# Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

> **NCT05982093** · PHASE2 · RECRUITING · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 96 (estimated)

## Conditions studied

- Breast Cancer
- HER2-negative Breast Cancer
- Hormone Receptor Positive Tumor
- Premenopausal Breast Cancer

## Interventions

- **DRUG:** Elacestrant
- **DRUG:** Triptorelin
- **DRUG:** Tamoxifen 20 mg

## Key facts

- **NCT ID:** NCT05982093
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-03
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05982093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05982093, "Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05982093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*